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ABSTRACT
Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two 
types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after 
botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving 
regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotu-
linum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid 
muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She 
recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when 
carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.
Keywords: Botulinum Toxins, Type A/adverse effects; Muscle Weakness/etiology; Upper Extremity
RESUMO
A toxina botulínica A foi aprovada para o tratamento da espasticidade em doentes pós-AVC. Os efeitos adversos são geralmente de 
dois tipos: efeitos adversos relacionados com a administração local de toxina botulínica A; e efeitos adversos sistémicos relacionados 
com a difusão à distância da toxina. A paresia muscular dos membros contralaterais após tratamento com toxina botulínica A é um 
efeito adverso raro. Descrevemos o caso de uma mulher de 33 anos de idade que recebia infiltrações regulares de toxina incobotulí-
nica A por espasticidade dos membros direitos pós-AVC hemorrágico. Foi feita uma troca para toxina abobotulínica A com um factor 
de conversão global de 1:3,83. A doente apresentou parésia do membro superior contralateral, especialmente do músculo deltóide. 
A electroneuromiografia foi compatível com bloqueio neuromuscular devido a toxina botulínica A. Recuperou totalmente após oito 
meses. A troca entre diferentes formulações de toxina botulínica A deve exigir precaução na conversão das unidades. Efeitos adversos 
à distância podem surgir, incluindo parésia dos membros contralaterais.
Palavras-chave: Fraqueza Muscular/etiologia; Membros Superiores; Toxinas Botulínicas Tipo A/efeitos adversos
INTRODUCTION
Botulinum toxin A (BoNT-A) has been approved for spasticity management. The most serious adverse effect is related 
to systemic spread, manifested by generalized weakness.1,2 We report a case of contralateral upper limb weakness in a 
patient who received BoNT-A injection for poststroke spasticity.
CASE REPORT
A 33-year-old white female with a history of hemorrhagic stroke started a rehabilitation program that included BoNT-A 
in the right upper and lower limbs for spasticity management. Injections were performed at three-month intervals for five 
years, always with Incobotulinum toxin A (Inco/A) 400 U, except during the Tower study,3 when she received one 600 U 
and one 800 U injection. Due to unavailability of Inco/A in our hospital, a switch to Abobotulinum toxin A had to be made. 
The new formulation injection was performed under ultrasonographic guidance. Approximately 10 days after injection, the 
caregivers noticed diminished muscle strength in the proximal left upper limb. The patient was assessed by her regular 
BoNT-A injector that found a paresis of the left shoulder flexors and abductors graded as 2 in the Medical Research Council 
scale; the left hemi-body sensitivity, reflexes and tonus were normal, as well as muscle strength in other muscle groups. 
The magnetic resonance imaging did not show any findings suggestive of acute lesions. The electroencephalography 
showed normal baseline electrogenesis. A cervical spine MRI did not show any significant findings. The electroneuromy-
ography (EMG) findings at day 21 and week 16 after injection are described in Table 1 and Table 2, respectively. Eighteen 
months after the patient’s last BoNT-A injection, the caregivers reported full recovery of her left shoulder flexors and abduc-
tors strength. It was decided to resume treatment with a switch back to 450 U of Inco/A. The patient has had good response 
to treatment, with adequate right hemi-body tonus control, and no further adverse effects.
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DISCUSSION
Previously described case reports
Muscle weakness contralateral to the injected side was found to be extremely rare in a systematic review.1 There are 
only three other case reports of patients who received BoNT for post-stroke spasticity and presented with contralateral 
upper extremity weakness.4,5 In the first described case, a 53-year-old woman received 800 U and 500 U of Ona/A, and 
developed contralateral weakness and fatigue two weeks after treatment. No electrophysiological testing was done in this 
case. In the following case, a 43-year-old woman received 700 U of Ona/A, and three weeks later presented with contralat-
eral upper extremity weakness. Upon electrophysiological testing, she revealed on slow (3-Hz) repetitive nerve stimulation 
of the left axillary nerve a 23% decrement in amplitude. EMG revealed abnormal spontaneous activity and polyphasic 
motor unit potential (MUP) with reduced recruitment in the left deltoid, biceps brachii, and infraspinatus (the only muscles 
tested for comfort). On the 2-month follow up visit, she had improved, but was still recovering. In the third case, a 21-year-
old woman, who had suffered a stroke when she was two years old, received 700 U of Ona/A, and developed contralateral 
upper limb weakness six weeks posttreatment. A 2-Hz repetitive stimulation of the spinal accessory nerve revealed a 16% 
decrease in amplitude. EMG showed mild abnormal spontaneous activity and small polyphasic motor unit potentials with 
reduced recruitment in the deltoids, biceps, infraspinatus and supraspinatus (the only muscles tested for patient comfort). 
In the 4-month follow up visit she had improved, but was still recovering. In the 5-month follow up visit she was reinjected 
and started to receive subsequent injections of 500 U of Ona/A, without injection of any muscle proximal to the elbow, and 
did not present further contralateral upper limb weakness. 
Similarities to our case report
In accordance with these three case reports, our patient was also female and presented with contralateral upper limb 
weakness (there was no weakness noted in the lower limb) in the second week following treatment. Electrophysiological 
testing was suggestive of dysfunction at the level of the motor endplate, showing, in slow (3-Hz) repetitive stimulation, 
a 45% – 48% decrease in amplitude. The EMG findings of fibrillations and/or positive waves in the left deltoideus and 
infraspinatus muscles, with decreased recruitment, and small amplitude polyphasic MUPs have been described in botulism 
and are attributed to severe blockade of the neuromuscular junction.6
Adverse events
Systemic adverse effects reported after BoNT limb muscles injection include muscle weakness distant to the injection 
site, dysphagia, and dry mouth, among others.1 Absorption of free BoNT may occur through the capillary system. It is also 
possible that a combination of vascular and neural spread occurs. Limited evidence exists of retrograde axonal spread in 
humans. Most evidence of this mechanism is derived from animal studies,1 and it is still unclear if the transported BoNT 
remains enzymatically active.7,8 Taking all into account, we believe that the most probable cause for contralateral weakness 
in our patient was ‘hematogenous spread’. Although BoNT can travel through muscle fascia, as hypothesized by Thomas 
and Simpson,5 we do not believe this to be the most plausible explanation, because: (1) the most proximal muscle injected 
in our patient was the biceps brachii (injected at half distance between the shoulder and the elbow); (2) there was no weak-
ness in the muscles present in the hypothetic subcutaneous or trans-fascial trajectory of BoNT until it reached contralateral 
deltoids (namely, there was no weakness of the coracobrachialis or any of the pectoralis muscles; (3) the ipsilateral deltoid 
muscle showed a smaller decrease in amplitude than the contralateral deltoid to low-frequency stimulation which would 
probably not have happened if we consider local diffusion gradients (higher proximal to the injection site); (4) if it was not 
osmotically but mechanically induced movement, it should not have affected the contralateral upper limb, because the 
trajectory that would have to be made was against gravity. Our hypothesis is that saturation of BoNT receptors occurred in 
one or more of the injection sites, and that unbounded BoNT was washed away from that/those regions by the circulatory 
system, specially the capillary system. Why did it affect predominantly the contralateral deltoid muscle (and not other mus-
cles, such as the orbicularis oculi or swallowing muscles) we do not know and it is a question that could be addressed in 
further studies. Perhaps it can have something to do with the deltoid muscle having a high blood flow,9 which could increase 
the probability of circulating unbound BoNT binding to the motor endplates at that anatomical region (increased number of 
unbounded BoNT molecules present at that site per unit of time) and not binding sufficiently in other muscles in order to 
produce clinical symptoms.
Dose equivalence 
The conversion ratio between Ona/A and Abo/A is still debated. Even if the most commonly quoted conversion ratios 
are 1:3 or 1:4,10 they range from 1:111; to as high as 1:11.12 However, in studies where the conversion ratio is higher than 
1:3, Abo/A showed higher efficacy and longer duration of action compared to Ona/A, but with more adverse events.13 In our 
case case the mean conversion factor of Inco:Abo was 1:3.83, which could have led to systemic BoNT diffusion. 
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CONCLUSION
Weakness of contralateral muscles to the injected side with BoNT is extremely rare and reported in very few studies. 
Physicians should be aware that a number of factors influence efficacy, diffusion and spread. In our patient, a global con-
version ratio of 1:3.83 was used, which seemed to be the determinant factor that caused system spread of BoNT. 
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Table 1 – Electroneuromyography at day 21 (third week post-toxin injection)
Sensitivity 
conduction study
Left median nerve (fingers 1 and 3) Normal
Left ulnar nerve Normal
Left radial nerve (superficial branch) Normal
Left lateral antebrachial cutaneous nerve Normal
Left medial antebrachial cutaneous nerve Normal
Motor conduction 
study
Bilateral axillary nerve Marked reduction of the left axillary nerve motor potential by comparison 
to the right axillary nerve. Normal latencies on left and right sides, without 
any significant asymmetries.
Bilateral musculocutaneous nerve Normal, without any significant asymmetries.
Left median nerve Normal, including the F waves.
Left ulnar nerve Normal, including the F waves.
Left radial nerve Normal, including the F waves.
Repetitive 
stimulation testing
Low frequency stimulation (3 Hz)
(at rest)
Left deltoideus 45% – 48% decrement in amplitude; 
57% – 64% decrement in area
Left anconeus 7% – 8% decrement in amplitude; 
9% – 10% decrement in area
Right deltoideus 6% – 13% decrement in amplitude; 
14% – 19% decrement in area
Right biceps brachii No decrement
Right trapezius No decrement
Right abductor digiti minimi No decrement
Abductor pollicis brevis No decrement
High frequency stimulation (20 Hz 
and 50 Hz)
Left deltoid No increment
Left anconeus No increment
Electromyography Fibrillations and/or positive waves in the left deltoideus and infra-spinatus muscles, with decreased activation, 
polyphasic PUM with small amplitude. 
Very sparse fibrillations in the left brachoradialis and biceps brachii, with normal recruitment pattern.
Left pronator teres, flexor carpi radialis, triceps brachii, extensor indicis, first dorsal interosseous and cervical 
erector spinae muscles without pathological findings.
Table 2 – Electroneuromyography at week 16th post-toxin injection
Repetitive 
stimulation testing
Low frequency stimulation (3 Hz)
(at rest)
Left deltoideus 20% – 27% decrement in amplitude; 
26% – 29% decrement in area
Left anconeus No decrement
Right deltoideus No decrement
